EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Classical and Late‐Onset SOS / VOD After Allogeneic HSCT : A Japanese Transplant Registry Analysis

Kyoko Masuda iD, Keisuke Kataoka, Masatoshi Sakurai, Yuho Najima iD, Naonori Harada, Shoko Ukita iD, Naoyuki Uchida iD, Noriko Doki, Takahiro Fukuda, Masatsugu Tanaka, Hiroyuki Ohigashi, Jun Ishikawa und 9 weitere

American Journal of Hematology · 2025

DOI: 10.1002/ajh.27715 ↗

Kurz gefasst

Fachartikel in der Zeitschrift American Journal of Hematology, 2025. Verfasst von Kyoko Masuda und 20 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology, Department of Medicine, Keio University School of Medicine, Tokyo, Japan. Hauptthemen laut MEDLINE: Hematopoietic Stem Cell Transplantation, Hepatic Veno-Occlusive Disease. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Sinusoidal obstruction syndrome/veno‐occlusive disease (SOS/VOD) is a lethal complication of allogeneic hematopoietic stem cell transplantation (allo‐HSCT). According to the 2016 European Society for Blood and Marrow Transplantation criteria, SOS/VOD is classified into classical SOS/VOD and late‐onset SOS/VOD, but their similarities and differences remain unclear. Here we retrospectively investigated the incidence, risk factors, and impact on transplant outcomes of classical and late‐onset SOS/VOD in 16 518 allo‐HSCT recipients using the Japanese nationwide registry data. The cumulative incidences of classical and late‐onset SOS/VOD were 2.5% and 2.2%, with a median onset of 13 and 42 days after transplantation, respectively. Both patients with classical (hazard ratio [HR], 3.45; 95% CI, 3.07–3.87) and late‐onset (HR, 3.98; 95% CI, 3.51–4.51) SOS/VOD had a significantly worse overall survival compared with those without. The risk factors for classical and late‐onset SOS/VOD are different. Hepatic comorbidities, high‐risk diseases, use of melphalan (MEL), and myeloablative conditioning are associated with both types of SOS/VOD. Whereas poor performance status, a prior history of transplantation, and positive hepatitis C virus are associated with only classical SOS/VOD, allo‐HSCT from cord blood or related human leukocyte antigen‐haploidentical donors, use of total body irradiation and busulfan (BU), and tacrolimus‐based graft‐versus‐host disease prophylaxis are associated with only late‐onset SOS/VOD. In particular, the incidence of late‐onset SOS/VOD is much higher in patients receiving both BU‐ and MEL‐containing conditioning regimens. These findings suggest that different monitoring and treatment approaches are necessary for allo‐HSCT recipients at high risk for classical and late‐onset SOS/VOD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hematopoietic Stem Cell TransplantationHepatic Veno-Occlusive DiseaseAdolescentAdultAgedFemaleHumansMaleMiddle AgedYoung AdultAllograftsIncidenceJapanMelphalanRegistriesRetrospective StudiesRisk FactorsTransplantation ConditioningTransplantation, Homologous

Stichwörter der Autor:innen

allogeneic hematopoietic stem cell transplantationclassical SOS/VODlate‐onset SOS/VODsinusoidal obstruction syndrome/veno‐occlusive disease

Substanzen

Melphalan

Autor:innen und Institutionen

  • Division of Hematology, Department of Medicine, Keio University School of Medicine, Tokyo, Japan.
  • Division of Molecular Oncology, National Cancer Center Research Institute, Tokyo, Japan.
  • Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan.
  • Department of Hematology, Fuchu Hospital, Izumi, Japan.
  • Hematology, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan.
  • Biostatistics Unit, Clinical and Translational Research Center, Keio University Hospital, Tokyo, Japan.

ORCID-Profile: Kyoko Masuda, Yuho Najima, Shoko Ukita, Naoyuki Uchida, Shuichi Ota, Yoshinobu Kanda, Hideki Nakasone, Kimikazu Yakushijin

Zitieren

APA

Masuda, K., Kataoka, K., Sakurai, M., Najima, Y., Harada, N., Ukita, S., Uchida, N., Doki, N., Fukuda, T., Tanaka, M., Ohigashi, H., Ishikawa, J., Yoshihara, S., Sawa, M., Ota, S., Kanda, Y., Nishida, T., Onizuka, M., Atsuta, Y., …, & Yakushijin, K. (2025). Classical and Late‐Onset SOS / VOD After Allogeneic HSCT : A Japanese Transplant Registry Analysis. American Journal of Hematology. https://doi.org/10.1002/ajh.27715

Vancouver

Masuda K, Kataoka K, Sakurai M, Najima Y, Harada N, Ukita S, et al. Classical and Late‐Onset SOS / VOD After Allogeneic HSCT : A Japanese Transplant Registry Analysis. American Journal of Hematology. 2025. doi:10.1002/ajh.27715

BibTeX
@article{Masuda2025,
  author = {Masuda, Kyoko and Kataoka, Keisuke and Sakurai, Masatoshi and Najima, Yuho and Harada, Naonori and Ukita, Shoko and Uchida, Naoyuki and Doki, Noriko and Fukuda, Takahiro and Tanaka, Masatsugu and Ohigashi, Hiroyuki and Ishikawa, Jun and Yoshihara, Satoshi and Sawa, Masashi and Ota, Shuichi and Kanda, Yoshinobu and Nishida, Tetsuya and Onizuka, Makoto and Atsuta, Yoshiko and Nakasone, Hideki and Yakushijin, Kimikazu},
  title = {Classical and Late‐Onset SOS / VOD After Allogeneic HSCT : A Japanese Transplant Registry Analysis},
  journal = {American Journal of Hematology},
  year = {2025},
  doi = {10.1002/ajh.27715}
}
Kostenlos starten →